Interviews

Elizabeth Jones, MD, FAAD, Thomas Jefferson University Hospitals, advocates for teledermatology as a vital tool to enhance health care equity by improving access for underserved populations and reducing physician burnout.

Rebecca Vasquez, MD, FAAD, University of Texas Southwestern Medical Center, emphasizes the necessity of addressing social determinants to improve dermatological care and access for underserved populations.

States must analyze the data on Medicaid and social determinant programs to understand the consequences of how potential policy changes will impact residents, Molly Dean, MSW, Siftwell, explains.

Rebecca Haberman, MD, of NYU Langone Health, highlights precision medicine and potential prevention strategies, two areas of promising psoriatic arthritis research.

Karen Winkfield, MD, PhD, addresses the importance of inclusive clinical trial participation and meeting patients where they are.

Lidia Schapira, MD, FASCO, professor of medicine at Stanford Medicine, medical oncologist, and director for the Stanford Cancer Institute and the Stanford Comprehensive Cancer Center, shares ways in which clinicians can help enhance patient engagement and shared decision-making.

Tiffany Meng, PharmD, oncology pharmacist, UCSF Health, discusses ways that pharmacists can help guide patients to financial assistance programs to help facilitate better access to breast cancer therapies.

Although her recent study acknowledges potential differences between White and non-White patients with psoriatic arthritis (PsA), Rebecca Haberman, MD, NYU Langone Health, emphasizes the need for further research to understand what these differences are and why they occur.

Gladys Antelo-Allen, Camden Coalition, shares the necessary skills to effectively equip supervisors to lead their teams and support individuals with complex health and social needs.

Jade E. Jones, MD, of Emory Winship Cancer Institute, shares how considering patients' travel needs, social services, and insurance concerns can help improve access to care.

Susan Escudier, MD, FACP, discusses the impact of insurance coverage gaps, transportation barriers, and financial hardships on cancer care access and emphasizes the need for payers to better support patients at high risk.

Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.

In the wake of novel bispecific and chimeric antigen receptor T-cell therapies for various cancers, geography still plays a big role in patients' abilities to receive such treatments.

In part 3 of this conversation, Karen Winkfield, MD, PhD, executive director of the Meharry-Vanderbilt Alliance, discusses why basic scientific research remains essential and how patient experiences contribute.

As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.

Antoine Keller, MD, founded HeartSense with the purpose of uncovering and addressing the cardiovascular needs of rural, often underserved communities.

Although psoriatic arthritis may be more prevalent in White patients, Rebecca Haberman, MD, of NYU Langone Health, emphasizes that the disease affects those across diverse racial and ethnic backgrounds.

Susan Escudier, MD, FACP, explains some of the ways Texas Oncology mitigates financial toxicity and improve clinical trial access for underserved patients.

Gladys Antelo-Allen, ​​associate director of education and training at Camden Coalition, dives into the foundational skills in complex care that can enhance provider education and facilitate trusting patient-provider relationships.

Joshua Kaufman, MD, medical director of Behavioral Health and Medical Integration at Capital District Physicians' Health Plan, outlines the progression of treatment approaches for comorbid schizophrenia and substance use disorder.

“To error is human, and also to error is in machine learning,” said Debra Patt, MD, PhD, MBA, MPH.

Debra Patt, MD, PhD, MBA, MPH, warns that prior authorization barriers are delaying critical cancer treatments and urges a regulatory fix for Stark Law restrictions on mailing oral oncolytics.

In this interview, chief operating officer and cofounder of Upfront Healthcare, Carrie Kozlowski, OT, MBA, discusses the integration of artificial intelligence (AI) in health care, emphasizing both opportunities and risks.

Debra Patt, MD, PhD, MBA, MPH, emphasizes advocacy for pharmacy benefit manager (PBM) reform, physician reimbursement, and sustainable policy solutions to improve access to community cancer care.

February 4 is World Cancer Day, and in these interviews with our Strategic Alliance Partner, NYU Langone Health, we learn about the importance of forming strong relationships with the communities you are located in and with whom you work to optimize cancer-related outcomes.

Sarah Anderson, oncology strategy lead director, Novotech, discusses the significance of triple-negative breast cancer research in the Asia-Pacific region, and the importance of clinical trial diversity in this region.

Gladys Antelo-Allen of Camden Coalition discusses a new skills lab offering accessible learning modules with 12 microlessons on best practices for approaching complex care.

On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.

In part 2 of our interview with Karen Winkfield, MD, PhD, she speaks to the importance of ensuring health care accessibility and of knowing that the health care system is not a one-size-fits-all arrangement.

Jessica Tracy, head of Growth and Partnerships at Enthea, shares how employers and unions can support mental health and address access barriers to evidence-based ketamine treatments.